Advertisement

Topics

FOCUS Clinical Drug Development GmbH Company Profile

10:21 EDT 26th September 2018 | BioPortfolio

FOCUS is an independent drug development organisation with 120 employees, offering full-service Phase I to III clinical development packages or individual service modules. The headquarters are located in Neuss/Duesseldorf, Germany with affiliates in Heidelberg, Moscow, Tokyo and Jakarta.

Location

Stresemannallee 6
Neuss
41460
Germany


News Articles [5940 Associated News Articles listed on BioPortfolio]

Bayer AG Teams Up with Evotec and Haplogen Amidst Monsanto Litigation Loss

Evotec AG and Haplogen GmbH have been long-term collaboration partners. The companies announced that Haplogen will enter into a multi-year drug discovery and development deal with Bayer AG to focus on...

Speeding Drug Development with Clinical Trials in a Dish

The average time to bring a new drug to market is 12 years—assuming it makes it through the rigorous regulatory hurdles. Any technology or methodology that can expedite the drug development process ...

Merrimack pancreatic drug fails, development halted

The oncology company, which saw its shares lose a third of their value Monday, is shifting focus to two earlier-stage assets, as well as its pre-clinical portfolio.

Avillion: Lewis Cameron, an innovative model for clinical development.

Lewis Cameron CEO, talks about the companies objective, with a strong focus on helping partners develop their drug candidate by incurring 100% of the clinical and regulatory risks, while Pharma will m...

Trial Simulation, Drug Selection To Be Focus Of US FDA's Drug Development Modeling Pilot

Meeting requests from sponsors that focus on safety prediction will also be prioritized.    

15% Reader Discount on Registration at the World Orphan Drug Congress Europe

The 9th annual World Orphan Drug Congress is the marketplace for orphan drug professionals looking at the complete value chain of orphan drug development, from clinical development and R&D to corp...

Boehringer injects €230 million in new Biologicals Development Center

Prominent industry player Boehringer Ingelheim has unveiled plans to invest €230 million into the construction of a new Biologicals Development Center in Germany. The investment is a bid to expand d...

How SkyePharma Makes Good Drugs Better

One important role of drug delivery companies is to improve or reposition existing drugs by the application of their own technologies. Christopher de Souza, VP Business Development, explains the techn...

PubMed Articles [8498 Associated PubMed Articles listed on BioPortfolio]

Clinical Pharmacology Considerations for Development of β Lactamase Inhibitor Combination with Antibiotics.

The shrinking drug pipeline for antibacterial drugs has made it very precious to discover and develop novel drugs in this space. In this context, the recent approvals of β lactamase inhibitors with e...

Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway.

In the USA, drugs are approved by the FDA by three main regulatory pathways: (i) 505(b)(1) new drug applications (NDAs); (ii) 505(b)(2) NDAs; and (iii) 505(j) abbreviated NDAs (ANDAs). The appropriate...

A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation.

Drugs can affect the cardiovascular (CV) system either as an intended treatment or as an unwanted side effect. In both cases, drug-induced cardiotoxicities such as arrhythmia and unfavourable hemodyna...

Next-generation sequencing in drug development: target identification and genetically stratified clinical trials.

Next-generation sequencing (NGS) enabled high-throughput analysis of genotype-phenotype relationships on human populations, ushering in a new era of genetics-informed drug development. The year 2017 w...

Is the pharmaceutical industry's preoccupation with the monotherapy drug model stifling the development of effective new drug therapies?

Drug discovery and development is heavily biased towards the development of monotherapies. Screening, testing, and evaluation of mono-entity drugs are generally much simpler than drug combinations, an...

Clinical Trials [6995 Associated Clinical Trials listed on BioPortfolio]

Development of a Clinical Trial Specific Question Prompt List

The purpose of this study is to develop a Question Prompt List (QPL) about clinical trials for cancer patients and find out what cancer patients and their caregivers think of the QPL. A QP...

XC8 in the Treatment of Patients With Bronchial Asthma

A multicenter, double-blind, randomized, parallel-group comparative Phase II clinical study to assess the efficacy and safety of different doses of XC8 vs Placebo in patients with partly c...

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

- Type: Bioequivalence study in male healthy volunteers, therapeutical indication (erectile disfunction) not studied - Products, dosage, and route of administration: ...

Computational Drug Repurposing for EBS

The study will compare gene expression differences between blistered and non-blistered skin from individuals with EBS, as well as normal skin from non-EBS subjects. State of the art comput...

Development of a Life Skills Intervention for Young Adolescents Perinatally-Infected With HIV and Their Caregivers

During this phase of the study, a focus group will be conducted with young adolescents perinatally infected with HIV and with their caregivers to develop and evaluate the content of the pr...

Companies [6175 Associated Companies listed on BioPortfolio]

FGK Clinical Research GmbH

As contract research organization FGK GmbH provides a wide range of services in drug and medical device development from early conception until final report. FGK has a focus on biotech companies which...

FOCUS Clinical Drug Development GmbH

FOCUS is an independent drug development organisation with 120 employees, offering full-service Phase I to III clinical development packages or individual service modules. The headquarters are located...

FAN GmbH

FAN GmbH - a centre of excellence for drug discovery with focus on diseases of the central nervous system Preclinical contract research - stroke and ischemia, Alzheimers disease,neuroprotection, neuro...

Avontec GmbH

AVONTEC GmbH is a phase II biopharmaceutical company engaged in the development of a novel class of anti-inflammatory drugs that are based on double-stranded DNA oligonucleotides acting as decoys (dec...

INNOPHAR GmbH

"The InnoPhaR GmbH is a clinical research organization with focus on the conduct of clinical studies in Eastern Europe. Besides first administration in man with young, healthy volunteers the main emph...

More Information about "FOCUS Clinical Drug Development GmbH" on BioPortfolio

We have published hundreds of FOCUS Clinical Drug Development GmbH news stories on BioPortfolio along with dozens of FOCUS Clinical Drug Development GmbH Clinical Trials and PubMed Articles about FOCUS Clinical Drug Development GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of FOCUS Clinical Drug Development GmbH Companies in our database. You can also find out about relevant FOCUS Clinical Drug Development GmbH Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Corporate Database Quicklinks



Searches Linking to this Company Record